Predicting Outcomes in Small Cell Lung Cancer with SII-PNI Score
Author Information
Author(s): Ge Yi, Liu Xiaoyu, Xu Yishi, Su Yanwei, Li Yixin, Wang Liping
Primary Institution: First Affiliated Hospital of Zhengzhou University
Hypothesis
The pre-treatment SII-PNI score can predict the tumor response and prognosis of extensive-stage SCLC patients treated with PD-L1 inhibitors and first-line chemotherapy.
Conclusion
The baseline SII-PNI score can serve as a reliable prognostic indicator for ES-SCLC patients receiving immunotherapy, with higher scores indicating a worse prognosis.
Supporting Evidence
- Patients with higher SII-PNI scores exhibited poorer survival outcomes.
- The SII-PNI score had an independent association with less favorable overall survival.
- The nomogram developed in the study was shown to be a reliable prognostic tool.
- Patients with lower SII-PNI scores had a higher likelihood of responding well to treatment.
Takeaway
Doctors can use a simple blood test score to help figure out how well treatment might work for patients with a type of lung cancer called SCLC.
Methodology
This study conducted a retrospective review of 70 ES-SCLC patients and analyzed their SII-PNI scores to assess overall survival and treatment response.
Potential Biases
The SII-PNI score may be influenced by factors unrelated to cancer, such as infections or medication use.
Limitations
The study had a limited sample size and lacked an external validation cohort.
Participant Demographics
The study included 70 patients, with 54 males (77.1%) and 16 females (22.9%), median age of 60 years.
Statistical Information
P-Value
p=0.008
Confidence Interval
95% CI, 11.4-23.4 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website